Humana Inc vs Palantir Technologies Inc — how do they compare? Humana Inc trades at $403.51 (market cap $47.81B), while Palantir Technologies Inc trades at $134 (market cap $323.28B). The key difference: Palantir Technologies Inc is far larger — about 6.8× Humana Inc's market cap, and Humana Inc pays a 0.89% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| HUM | PLTR | |
|---|---|---|
Market Cap | $47.81B | $323.28B |
Sector | Health | Technology |
52-Week High | $409.42 | $207.18 |
52-Week Low | $163.67 | $107.27 |
Enterprise Value | $56.85B | $315.46B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Palantir (PLTR) trades at $135.63, up 2.46% today, showing strong momentum despite being 35% below its 52-week high. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company demonstrates exceptional growth with 2025 revenue of $4.48 billion and net income of $1.63 billion, though valuation metrics remain elevated with a P/E of 148.74 and P/S of 65.12. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.33 surpassing the $0.2774 forecast.
Palantir's AI software leadership and accelerating revenue growth present compelling long-term potential, but the premium valuation creates significant risk if growth moderates. Analyst consensus leans bullish with a $185.75 price target, though the stock faces headwinds from competitive pressures and market rotation out of high-multiple software names. The company's strong government contracts and commercial expansion provide stability, but investors should weigh rich multiples against execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →